Rexahn Announces Move to Nasdaq
May 28 2019 - 4:10PM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage
biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat,
today announced that it will voluntarily transfer its stock
exchange listing to the Nasdaq Capital Market from its current
listing on NYSE American.
“As home to many innovative and growth-oriented life science
companies, Nasdaq is a natural fit for Rexahn,” said Douglas
Swirsky, president and chief executive officer of Rexahn. “We
believe the move to Nasdaq will provide strong visibility for our
stock, excellent trading liquidity in our shares, and greater
exposure to institutional investors.”
The Company expects to begin trading on Nasdaq under the symbol
"REXN" on or about June 10, 2019. The Company's common stock will
continue trading on NYSE American under the symbol "RNN" until the
move is completed.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical
stage biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat.
The Company’s mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn’s product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that several
of Rexahn’s product candidates may be effective against multiple
types of cancer, including drug resistant cancers,
difficult-to-treat cancers and others, may augment the
effectiveness of current FDA-approved cancer treatments. The
Company has two oncology product candidates, RX-3117 and RX-5902,
in Phase 2 clinical development and additional compounds in
preclinical development, including RX-0301. For more information
about the Company and its oncology programs, please visit
www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
regarding expectations and intentions with respect to Rexahn’s
listing and trading of its common stock on the Nasdaq Capital
Market, Rexahn’s plans, objectives, expectations and intentions
with respect to future operations and products, the path of
clinical trials and development activities, and other statements
identified by words such as “will,” “potential,” “could,” “can,”
“believe,” “intends,” “continue,” “plans,” “expects,”
“anticipates,” “estimates,” “may,” and other words of similar
meaning or the use of future dates. Forward-looking statements by
their nature address matters that are, to different degrees,
uncertain. Uncertainties and risks may cause Rexahn’s actual
results to be materially different than those expressed in or
implied by Rexahn’s forward-looking statements. For Rexahn,
particular uncertainties and risks include, among others,
understandings and beliefs regarding the role of certain biological
mechanisms and processes in cancer; drug candidates being in early
stages of development, including clinical development; the ability
to initially develop drug candidates for orphan indications to
reduce the time-to-market and take advantage of certain incentives
provided by the U.S. Food and Drug Administration; the ability to
transition from our initial focus on developing drug candidates for
orphan indications to candidates for more highly prevalent
indications; the availability and access to capital; and the
expected timing of results from our clinical trials. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and quarterly report on Form 10-Q. All
forward-looking statements in this news release speak only as of
the date of this news release. Rexahn undertakes no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise.
Investor Contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024